<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <!-- common.css -->
  <style>* {-webkit-tap-highlight-color: rgba(0,0,0,0);}html {-webkit-text-size-adjust: none;}body {font-family: Arial, Helvetica, sans-serif;margin: 0;color: #333;word-wrap: break-word;}h1, h2, h3, h4, h5, h6 {line-height: 1.1;}img {max-width: 100% !important;}blockquote {margin: 0;padding: 0 15px;color: #777;border-left: 4px solid #ddd;}hr {background-color: #ddd;border: 0;height: 1px;margin: 15px 0;}code {font-family: Menlo, Consolas, 'Ubuntu Mono', Monaco, 'source-code-pro', monospace;line-height: 1.4;margin: 0;padding: 0.2em 0;font-size: 85%;background-color: rgba(0,0,0,0.04);border-radius: 3px;}pre {margin: 0;}pre > code {margin: 0;padding: 0;font-size: 100%;word-break: normal;background: transparent;border: 0;}ol {list-style-type: decimal;}ol ol, ul ol {list-style-type: lower-latin;}ol ol ol, ul ol ol, ul ul ol, ol ul ol {list-style-type: lower-roman;}table {border-spacing: 0;border-collapse: collapse;margin-top: 0;margin-bottom: 16px;}table th {font-weight: bold;}table th, table td {padding: 6px 13px;border: 1px solid #ddd;}table tr {border-top: 1px solid #ccc;}table tr:nth-child(even) {background-color: #f8f8f8;}input[type="checkbox"] {cursor: default;margin-right: 0.5em;font-size: 13px;}.task-list-item {list-style-type: none;}.task-list-item+.task-list-item {margin-top: 3px;}.task-list-item input {float: left;margin: 0.3em 1em 0.25em -1.6em;vertical-align: middle;}#tag-field {margin: 8px 2px 10px;}#tag-field .tag {display: inline-block;background: #cadff3;border-radius: 4px;padding: 1px 8px;color: black;font-size: 12px;margin-right: 10px;line-height: 1.4;}</style>
  <!-- ace-static.css -->
  <style>.ace_static_highlight {white-space: pre-wrap;}.ace_static_highlight .ace_gutter {width: 2em;text-align: right;padding: 0 3px 0 0;margin-right: 3px;}.ace_static_highlight.ace_show_gutter .ace_line {padding-left: 2.6em;}.ace_static_highlight .ace_line {position: relative;}.ace_static_highlight .ace_gutter-cell {-moz-user-select: -moz-none;-khtml-user-select: none;-webkit-user-select: none;user-select: none;top: 0;bottom: 0;left: 0;position: absolute;}.ace_static_highlight .ace_gutter-cell:before {content: counter(ace_line, decimal);counter-increment: ace_line;}.ace_static_highlight {counter-reset: ace_line;}</style>
  <style>.ace-chrome .ace_gutter {background: #ebebeb;color: #333;overflow : hidden;}.ace-chrome .ace_print-margin {width: 1px;background: #e8e8e8;}.ace-chrome {background-color: #FFFFFF;color: black;}.ace-chrome .ace_cursor {color: black;}.ace-chrome .ace_invisible {color: rgb(191, 191, 191);}.ace-chrome .ace_constant.ace_buildin {color: rgb(88, 72, 246);}.ace-chrome .ace_constant.ace_language {color: rgb(88, 92, 246);}.ace-chrome .ace_constant.ace_library {color: rgb(6, 150, 14);}.ace-chrome .ace_invalid {background-color: rgb(153, 0, 0);color: white;}.ace-chrome .ace_fold {}.ace-chrome .ace_support.ace_function {color: rgb(60, 76, 114);}.ace-chrome .ace_support.ace_constant {color: rgb(6, 150, 14);}.ace-chrome .ace_support.ace_type,.ace-chrome .ace_support.ace_class.ace-chrome .ace_support.ace_other {color: rgb(109, 121, 222);}.ace-chrome .ace_variable.ace_parameter {font-style:italic;color:#FD971F;}.ace-chrome .ace_keyword.ace_operator {color: rgb(104, 118, 135);}.ace-chrome .ace_comment {color: #236e24;}.ace-chrome .ace_comment.ace_doc {color: #236e24;}.ace-chrome .ace_comment.ace_doc.ace_tag {color: #236e24;}.ace-chrome .ace_constant.ace_numeric {color: rgb(0, 0, 205);}.ace-chrome .ace_variable {color: rgb(49, 132, 149);}.ace-chrome .ace_xml-pe {color: rgb(104, 104, 91);}.ace-chrome .ace_entity.ace_name.ace_function {color: #0000A2;}.ace-chrome .ace_heading {color: rgb(12, 7, 255);}.ace-chrome .ace_list {color:rgb(185, 6, 144);}.ace-chrome .ace_marker-layer .ace_selection {background: rgb(181, 213, 255);}.ace-chrome .ace_marker-layer .ace_step {background: rgb(252, 255, 0);}.ace-chrome .ace_marker-layer .ace_stack {background: rgb(164, 229, 101);}.ace-chrome .ace_marker-layer .ace_bracket {margin: -1px 0 0 -1px;border: 1px solid rgb(192, 192, 192);}.ace-chrome .ace_marker-layer .ace_active-line {background: rgba(0, 0, 0, 0.07);}.ace-chrome .ace_gutter-active-line {background-color : #dcdcdc;}.ace-chrome .ace_marker-layer .ace_selected-word {background: rgb(250, 250, 255);border: 1px solid rgb(200, 200, 250);}.ace-chrome .ace_storage,.ace-chrome .ace_keyword,.ace-chrome .ace_meta.ace_tag {color: rgb(147, 15, 128);}.ace-chrome .ace_string.ace_regex {color: rgb(255, 0, 0)}.ace-chrome .ace_string {color: #1A1AA6;}.ace-chrome .ace_entity.ace_other.ace_attribute-name {color: #994409;}.ace-chrome .ace_indent-guide {background: url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAACCAYAAACZgbYnAAAAE0lEQVQImWP4////f4bLly//BwAmVgd1/w11/gAAAABJRU5ErkJggg==") right repeat-y;}</style>
  <!-- export.css -->
  <style>
    body{margin:0 auto;max-width:800px;line-height:1.4}
    #nav{margin:5px 0 10px;font-size:15px}
    #titlearea{border-bottom:1px solid #ccc;font-size:17px;padding:10px 0;}
    #contentarea{font-size:15px;margin:16px 0}
    .cell{outline:0;min-height:20px;margin:5px 0;padding:5px 0;}
    .code-cell{font-family:Menlo,Consolas,'Ubuntu Mono',Monaco,'source-code-pro',monospace;font-size:12px;}
    .latex-cell{white-space:pre-wrap;}
  </style>
  <!-- User CSS -->
  <style> .text-cell {font-size: 15px;}.code-cell {font-size: 12px;}.markdown-cell {font-size: 15px;}.latex-cell {font-size: 15px;}</style>
</head>
<body>
  <div id="nav"><div>Next: <a href='Lymphomas.html'>Lymphomas</a>, Previous: <a href='Blood Banking and Transfusion Medicine.html'>Blood Banking and Transfusion Medicine</a>, Up: <a href='index.html'>Index</a></div></div>
  <div id="titlearea">
    <h2>Leukemias</h2>
  </div>
  <div id="contentarea"><div class="cell markdown-cell"><h1 id="acute-leukemias">Acute Leukemias</h1>
<h2 id="acute-myeloid-leukemia">Acute Myeloid Leukemia</h2>
<p>Neoplastic Proliferation of myeloblasts. <strong>Diagnosis requires &gt;20% myeloblasts in bone marrow</strong>. AML is an oligoclonal disease.<br>General Features:</p>
<ul>
<li>Older adults</li><li>Symptoms: <ul>
<li>Fatigue, bruising, B symptoms, petechiae</li><li><strong>Gum infiltration in monocytic AML</strong></li><li><strong>Sweet's Syndrome - myeloid luekemia cells infiltrate the skin</strong> and Chloromas (node-like masses under the skin)</li></ul>
</li><li><strong>Lymphoma Therapy can cause AML</strong> 5-15 years later</li><li>Peripheral blood smear appearance: blasts with <strong>Auer rods</strong> (crystal aggregates of <strong>myeloperoxidase</strong>), <strong>primary granules</strong></li><li>Treatment:<ul>
<li>APL - chemo + ATRA</li><li>Non-APL - <strong>induction</strong> chemo + <strong>consolidation</strong> chemo (no maintenance)</li></ul>
</li></ul>
<h3 id="acute-promyelocytic-leukemia-apl-or-aml-m3-">Acute Promyelocytic Leukemia (APL or AML M3)</h3>
<ul>
<li>t(<strong>15;17</strong>) =&gt; translocation of <strong>Retinoic Acid Receptor</strong>, <strong>PML</strong> blocks RAR<ul>
<li>Blocks maturation of myeloblasts</li></ul>
</li><li>Abnormal promyelocytes contain primary granules that build up and are released =&gt; <strong>DIC</strong></li><li>Treat with <strong>all-trans-retinoic acid</strong> (ATRA), causing cells to mature and die<ul>
<li>Can lead to <strong>cytokine storm (ATRA)</strong></li></ul>
</li></ul>
<h3 id="acute-monocytic-leukemia">Acute Monocytic Leukemia</h3>
<ul>
<li>Proliferation of monoblasts that usually lacks MPO</li><li><strong>Infiltrates gums</strong></li></ul>
<h3 id="acute-megakaryoblastic-leukemia">Acute Megakaryoblastic Leukemia</h3>
<ul>
<li>Proliferation of megakaryoblasts that usually lacks MPO</li><li>Associated with <strong>Downs syndrome</strong></li></ul>
<hr>
<h2 id="acute-lymphoid-leukemia">Acute Lymphoid Leukemia</h2>
<p>A neoblastic proliferation of T cell or B cell precursors (lymphoblasts). <strong>Diagnosis requires &gt;25% lymphoblasts in bone marrow</strong>.<br>General Featuers:</p>
<ul>
<li>All lymphoblasts are <strong>TdT+</strong>, therefore TdT staining is used to identify them</li><li>More common in children. Younger than 1 or older than 30 =&gt; worse prognosis than 1-30</li><li>Symptoms: bruising, fatigue, dyspnea, B symptoms, petechiae</li><li>Can cross blood barriers =&gt; <strong>CNS and Testes prophylaxis</strong> is necessary</li><li>Treatment:<ul>
<li>Favorable prognostic factors =&gt; <strong>chemotherapy</strong> alone - Induction, consolidation, delayed intensification, 2 years maintenance</li><li>Unfavorable prognostic factors, relapsed disease =&gt; <strong>chemotherapy</strong> to induce remission, then <strong>allogeneic HSC transplant</strong></li></ul>
</li></ul>
<table>
<thead>
<tr>
<th>Good Prognostic Factors</th>
<th>Bad Prognostic Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 1-30</td>
<td>Age &lt;1 or &gt;30</td>
</tr>
<tr>
<td>Hyperdiploidy</td>
<td>Hypodiploidy</td>
</tr>
<tr>
<td>TEL-AML1 (12;21) fusion</td>
<td>MLL abnormalities like t(4;11); Burkitt subtype</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th>Subtype</th>
<th>Cell Type</th>
<th>Clinical Features</th>
<th>Lab Findings</th>
<th>Extras</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-ALL</td>
<td>B cell precursor lymphoblasts</td>
<td>Good response to chemotherapy</td>
<td>CD10+, CD19+, CD20+ (B cell markers)</td>
<td>t(<strong>12;21</strong>) =&gt; <strong>good</strong> prognosis, more common in children; t(<strong>9;22</strong>) =&gt; <strong>poor</strong> prognosis, more common in <strong>adults</strong>, causes vacuoles in blast cytoplasm (Phi+ ALL)</td>
</tr>
<tr>
<td>T-ALL</td>
<td>T cell precursor lymphoblasts</td>
<td>Present as mediastinal (thymic) mass in teenagers</td>
<td>CD2-CD8+ (<strong>CD10-</strong>)</td>
<td>aka Acute Lymphoblastic Lymphoma (due to thymic mass)</td>
</tr>
</tbody>
</table>
<hr>
<h1 id="chronic-leukemias">Chronic Leukemias</h1>
<h2 id="chronic-myeloid-leukemia">Chronic Myeloid Leukemia</h2>
<p>Neoplastic proliferation of mature myeloid cells. </p>
<h3 id="pathogenesis">Pathogenesis</h3>
<ul>
<li>t(<strong>9;22</strong>) =&gt; <strong>Philadelphia</strong> Chromosome =&gt; <strong>BCR-ABL fusion</strong>, causing <strong>overactive tyrosine kinase</strong></li><li>Different proteins indicate different variants of CML/ALL that are caused by 9;22 transfusion<br>|BCR-ABL Protein|Associated Disease|<br>|---------------|------------------|<br>|<strong>P190</strong>|ALL, 9;22 variant|<br>|<strong>P210</strong>|CML|<br>|<strong>P230</strong>|<strong>Neutrophilic</strong> CML|</li></ul>
<h3 id="clinical-features">Clinical Features</h3>
<ul>
<li>Older adults</li><li>Many are asymptomatic and routine CBC shows <strong>high WBC</strong></li><li>Weight loss, fever, night sweats, early satiety (organomegaly)</li><li><strong>Splenomegaly</strong> (indicates accelerated disease w/ possibility of transformation to <strong>AML (more common) or ALL</strong> (<strong>"blast crisis"</strong>)</li></ul>
</div><div class="cell text-cell"><img src="resources/EBF85BE5CD274D22674B1336075A17E5.png" alt="Screen Shot 2016-02-19 at 10.41.57 AM.png"></div><div class="cell markdown-cell"><h3 id="lab-pathology-findings">Lab / Pathology Findings</h3>
<ul>
<li>Very low Leukocyte Alkaline Phopshatase (LAP)</li><li>Peripheral blood smear:<ul>
<li>Increased platelets and <strong>basophils</strong></li><li>Leukocytosis (mostly neutrophils)</li><li>Myelocyte bulge</li><li>Micromegakaryocytes (less lobulated megakaryocytes)</li></ul>
</li><li>Over time, progresses to <strong>fibrosis</strong></li><li><strong>PCR (more sensitive) and FISH</strong> probe shows BCR-ABL fusion (9;22)<ul>
<li>Repeated PCR is used to monitor BCR-ABL during treatment</li></ul>
</li></ul>
<h3 id="treatment">Treatment</h3>
<p><strong>Imatinib</strong>: blocks tyrosine kinase activity</p>
<hr>
<h2 id="chronic-lymphocytic-leukemia">Chronic Lymphocytic Leukemia</h2>
<p>Neoplastic proliferation of <strong>na√Øve B cells</strong> that are <strong>CD5 and CD20 positive</strong>. B cells are unable to undergo apoptosis</p>
<h3 id="pathogenesis">Pathogenesis</h3>
<ul>
<li>Monoclonal proliferation =&gt; elevated kappa OR lambda light chain</li><li>Leads to autoimmune disorders:<ul>
<li>Hemolytic anemia</li><li>ITP</li><li>Agranulocytosis</li><li>Hypogammaglobulinemia - <strong>infection = most common cause of death</strong></li></ul>
</li></ul>
<h3 id="clinical-features">Clinical Features</h3>
<ul>
<li>Older adults, <strong>most common adult leukemia</strong></li><li>Slow progression</li><li>Can involve lymph nodes (small lymphocytic lymphoma)</li><li>High risk of secondary skin cancers</li><li>Associated with <strong>Autoimmune Disorders</strong></li><li>Other symptoms are similar to CML</li></ul>
<h3 id="lab-pathology-findings">Lab/Pathology Findings</h3>
<ul>
<li>Peripheral blood smear: <strong>Smudge cells, increased lymphocytes</strong></li><li><strong>Thrombocytopenia indicates late stage disease</strong></li><li>Absolute Lymphocyte Count &gt; 10,000 is required for diagnosis</li></ul>
<table>
<thead>
<tr>
<th>Good Prognostic Factor</th>
<th>Bad Prognostic Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>VDJ mutation/recombination already occured (differentiation)</td>
<td>No mutation in Ig heavy chain</td>
</tr>
<tr>
<td>ZAP-70 negative</td>
<td>ZAP-70+</td>
</tr>
<tr>
<td></td>
<td>17p deletion (p53)</td>
</tr>
</tbody>
</table>
<h3 id="treatment">Treatment</h3>
<p>Monoclonal Antibody plus chemotherapy</p>
</div></div>
  <script>document.body.onkeyup = function(e) {
if (e.keyCode === 39) window.location.href = 'Lymphomas.html';
if (e.keyCode === 37) window.location.href = 'Blood Banking and Transfusion Medicine.html';
}</script>
</body>
</html>